Myosteatosis:
Muscle Quality as a New Cardiometabolic Biomarker
Myosteatosis, characterized by fat infiltration into skeletal muscle, is an emerging biomarker of systemic metabolic dysfunction. AI-driven measurement of thoracic skeletal muscle density from CAC scans has shown strong predictive value for HF, AF, CHD), and all-cause mortality. Recent studies demonstrate that combining myosteatosis with CAC scores amplifies risk prediction, particularly for males, making it a critical addition to AI-CVD®.
Enhanced Risk Stratification with AI-CVD®
HeartLung's AI-CVD® utilizes advanced AI algorithms to measure thoracic skeletal muscle density from CAC scans. This data, when combined with CAC scores, enhances the predictive accuracy for various cardiovascular conditions, particularly in males. The comprehensive evaluation provided by AI-CVD® enables early intervention and personalized treatment plans, helping to manage and mitigate the risks associated with myosteatosis and systemic metabolic dysfunction.
AI-CVD™ Emphysema Index on 5800 MESA Cases: RUL (Right Upper Lobe)
Clinical Implications of Myosteatosis
Myosteatosis involves the infiltration of fat into skeletal muscle, which can significantly impact muscle function and overall metabolic health. This condition is associated with systemic metabolic dysfunction, increasing the risk of heart failure, atrial fibrillation, coronary heart disease, and all-cause mortality. By incorporating myosteatosis measurements into HeartLung's AI-CVD® assessments, healthcare professionals can gain a deeper understanding of a patient's cardiometabolic health.
